Bocom Intl: rates the Mainland pharmaceutical industry as "leading", focusing on innovative and consumer-driven targets.

Zhitong FinanceOct 17, 2024 09:53

Pioneering the Pharmaceutical Industry (09939.HK): Pucluramide and Frethane have made many advances, allotted shares and increased cash availability

興業證券Sep 2, 2022 00:00

Pioneering Pharmaceutical-B (09939.HK): Pucluramide, which focuses on AR targets, is expected to be approved to treat COVID-19

國金證券Apr 11, 2022 00:00

Kaituo Pharmaceutical-B (09939.HK) 2021 Interim Report Review: Core Product Clinical Trials Advance Smoothly: Clinical Trials of Core Products Proceed Successfully, the Specific Oral COVID-19 Drug Pucluramide Wins First EUA

東吳證券Sep 2, 2021 00:00

Pioneering Pharmaceutical-B (9939.HK): Strong pipeline advancement

華泰證券Aug 31, 2021 00:00

Pioneering Pharmaceutical-B (09939.HK): Actively preparing for commercialization and focusing on disclosure of key clinical data

中金公司Aug 29, 2021 00:00

Pioneering Pharmaceutical-B (09939.HK): The pipeline layout is getting fuller, and commercialization of core products begins

中金公司Aug 12, 2021 00:00

Pioneering Pharmaceutical-B (9939.HK): Global expansion of procluramide sets sail

華泰證券Jul 21, 2021 00:00

Pioneering Pharmaceutical-B (9939.HK): Pioneering COVID-19 Treatment Ushers in New Opportunities

華泰證券Jun 9, 2021 00:00

Pioneering Pharmaceutical-B (9939.HK) Pioneering Portraits: Starting with COVID-19 Oral Specific Drugs, Opening Up the Sea of Stars for AR Applications

東吳證券May 31, 2021 00:00

Overseas Healthcare Sector Weekly Report: BeiGene updates zebutinib research data, biotechnology sector leads the industry

富途證券May 2, 2021 15:30

Pioneering Pharmaceutical-B (09939.HK) In-depth Research Report: Leading AR Industry Has Great Potential for COVID-COVID/Hair Loss/Acne Indications

華創證券Mar 19, 2021 00:00

First coverage of Pioneer Pharmaceutical (9939.HK): Accelerating R&D pipeline commercialization based on AR platforms is imminent

安信國際Mar 16, 2021 00:00

Pioneer Pharmaceutical-B (9939.HK) 1H20 performance: pucluramide is expected to submit NDA in China in 4Q20

浦銀國際Aug 26, 2020 00:00

Pioneer Pharmaceutical (9939.HK): An innovator in drug development for AR-related diseases; first coverage gave a “buy” rating

華菁證券Jul 17, 2020 00:00

Kaituo Pharmaceutical Co., Ltd. (9939.HK)

中泰國際May 12, 2020 00:00

Pioneer Pharmaceutical (09939.HK)

財通國際May 12, 2020 00:00

Kaituo Pharmaceutical Co., Ltd. - B (9939.HK): IPO News

致富證券May 12, 2020 00:00